ECMELLA as a Bridge to Recovery after Heart Transplantation—A Case Series

Background: Veno-arterial extracorporeal membrane oxygenation (va-ECMO) is increasingly used to treat cardiogenic shock. Recent studies showed that additional left ventricular unloading using a microaxial pump (Impella) may be associated with lower mortality. After heart transplantation, data on the combined use of va-ECMO and Impella (ECMELLA) are scarce. The aim of this study was to characterize patients who received an “ECMELLA” procedure for primary graft failure after HTX.

Methods: This monocentric, retrospective study included patients who received ECMELLA therapy for primary graft failure after HTX at the University Hospital Duesseldorf in the period 2010–2024 (Ethics Reference No.: 4567). Patients who received only va-ECMO without Impella support were excluded. The decision for ECMELLA therapy was based on echocardiographic and clinical evaluation. All available patient- and procedure-related data were analyzed.

Results: Out of 329 available patient cases in the database, 8 ECMELLA patients (2.4%) were identified and included. Mean age of the cohort was 55 ± 10 years and 37.5% of the patients were female. The mean duration of ECMELLA support was 12 ± 8 days. The mean durations of surgery and cardiopulmonary bypass were 8 ± 2.4 hours and 4.7 ± 1.7 hours, respectively. Intraoperatively, patients received 14 ± 8 units of packed red blood cells (PRBC; 1 unit = 270 mL), and 11 ± 8 units of fresh frozen plasma (FFP; 1 unit = 300 mL). Postoperatively, patients received 61 ± 28 units PRBCs and 55 ± 27 units FFP. ⅞ of the included patients (87.5%) required early open-chest revision surgery. On average, patients remained in the intensive care unit for 45 ± 31 days. Postoperative duration of mechanical ventilation was 19 ± 14 days and every patient received renal replacement therapy. The survival rate after 30 days was 62.5%.

Conclusion: ECMELLA for primary graft failure after HTX is a resource-intensive procedure that may be associated with a favorable outcome in select patients. Future research should try to identify criteria which patients may benefit from ECMELLA after HTX.

 

MissingLinkText

No conflict of interest has been declared by the author(s).

Publication History

Article published online:
11 February 2025